Sign up USA
Proactive Investors - Run By Investors For Investors

VolitionRx signs MoU with National Taiwan University for two large clinical studies

Cameron Reynolds, president and chief executive of VolitionRx Ltd (NYSEAMERICAN:VNRX) caught up with Proactive to chat through the group's Q3 update as well as the news they've signed a memorandum of understanding with the National Taiwan University to conduct two large clinical studies.

The studies will entail taking some 7,000 patient samples.

he first trial would be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific region, including 5,000 asymptomatic colorectal cancer screening subjects.

The second trial will include up to 2,000 symptomatic colorectal cancer patients.

 
Meet Tower Resources PLC, Arc Minerals Limited, Carbon Tracker, Tekcapital PLC and Serinus Energy at our event, London , 31 May 2018. Register here »
View full VNRX profile View Profile

VolitionRx Timeline

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use